Our Blog

Lidya Domínguez has been working at Sermes CRO since 2006. Before her new appointment, she worked as Head of the Clinical Trials Start-up Unit, as well as the Project Control Unit.

Sermes CRO’s new Director of Clinical Research is an expert in the clinical trials European regulation (EU Clinical Trial Regulation 536/2014). Since 2017, she has been part of the EMA’s  (European Medicines Agency) working group about CTIS, representing Sermes CRO. Composed of 15 experts, this group aims to accelerate the implementation of the new clinical trials portal (CTIS: Clinical Trial Information System).

As an expert in clinical trial management for pharmaceutical laboratories, biotechnology companies and independent researchers, she has focused on therapeutic areas such as oncology, advanced and cellular therapies, endocrinology, vaccines and infectious diseases.

She leads a team of more than 120 people and has been the architect, together with Sermes CRO’s CEO, Antonio Berlanga, of the Clinical Research Department restructuring, distributed in the Consulting and Clinical Regulation units; Contracts and Finances; Trial Master File (TMF & eTMF); Medical Writing; Project Controller; Clinical Monitoring; Pharmacovigilance; Management of Clinical Documentation and Translations; as well as the area of ​​Consulting and Management of Advanced Therapies.

“Lidya Domínguez’s ability to lead changes, coordinate projects and people, as well as her constant focus on innovation, in line with our strategy as Innovative CRO, are the origin of her appointment as Director of Clinical Research. Without a doubt, having Lidya in the direction of the company is a safe bet for us”, says Antonio Berlanca, CEO of Sermes CRO.